Sugi Predict

Sugi Predict / Compounds / SCHEMBL379161

SCHEMBL379161

SCHEMBL379161

COc1ccccc1-c1nc(CCl)no1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 13/20 0.60
▸ NPC1 O15118 12/20 0.60
▸ L3MBTL1 Q9Y468 4/20 0.60
▸ NPSR1 Q6W5P4 2/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ ALDH1A1 P00352 9/20 0.56
▸ SMN1; SMN2 Q16637 12/20 0.56
▸ GAA P10253 2/20 0.56
▸ TP53 P04637 10/20 0.56
▸ HSD17B10 Q99714 7/20 0.56
▸ HPGD P15428 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ NFKB1 P19838 2/20 0.56
▸ NFKB2 Q00653 2/20 0.56
▸ RELA Q04206 2/20 0.56
▸ KDM4E B2RXH2 6/20 0.55
▸ PKM P14618 1/20 0.55
▸ RXFP1 Q9HBX9 1/20 0.55
▸ MAPT P10636 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92319 0.86 RAB9A (0.58) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL13461952 0.85 RAB9A (0.57) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL10202917 0.82 RAB9A (0.55) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL4375583 0.81 L3MBTL1 (0.70) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL5660762 0.78 RAB9A (0.61) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL9674957 0.78 NPC1 (0.56) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL12072153 0.76 NPC1 (0.57) RAB9ANPC1L3MBTL1TDP1ALDH1A1
SCHEMBL5660757 0.76 RAB9A (0.60) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL12692348 0.76 RAB9A (0.67) RAB9ANPC1L3MBTL1NPSR1ALDH1A1
SCHEMBL3035463 0.75 NPC1 (0.51) RAB9ANPC1L3MBTL1NPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763509-B1 ALPHA-HELICAL MIMETICS WALTER & ELIZA HALL INST MEDICAL RES (AU) 2018-02-21 — — EP disclosed
US-9884832-B2 Inhibitors targeting drug-resistant influenza A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-02-06 — — US disclosed
CN-102947299-B Alkaloid aminoester derivatives and pharmaceutical compositions thereof CHIESI FARMA SPA 2015-07-15 — — CN disclosed
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-07-09 — — US disclosed
US-8778966-B2 Quinolinone derivatives as PARP and tank inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-07-15 — — US disclosed
US-8673948-B2 Chemical compounds GlaxoSmithKline, LLC (US) 2014-03-18 — — US disclosed
EP-2079466-B1 SUBSTITUTED INDOLE COMPOUNDS GLAXOSMITHKLINE LLC (US) 2014-01-15 — — EP disclosed
WO-2013086131-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-06-13 — — WO disclosed
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 — — US disclosed
US-20130123280-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS GILEAD SCIENCES, INC. (US) 2013-05-16 — — US disclosed
US-20030229106-A1 A2B adenosine receptor antagonists GILEAD SCIENCES, INC. 2003-12-11 — — US disclosed
US-20030139428-A1 A2B adenosine receptor antagonists GILEAD SCIENCES, INC. 2003-07-24 — — US disclosed
US-20030134853-A1 Compounds useful for treating hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY 2003-07-17 — — US disclosed
WO-2003042214-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-05-22 — — WO disclosed
WO-2003026587-A2 COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-03 — — WO disclosed
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 — — EP disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 — — EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 — — US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 — — WO disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A HAVCR2, HDLBP, HSP90B1 RAB9A 1566/4885NPC1 706/4885L3MBTL1 3544/4885
US-20030139428-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA1 RAB9A 1699/4885NPC1 2057/4885L3MBTL1 2716/4885
US-20030229106-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA1 RAB9A 1699/4885NPC1 2057/4885L3MBTL1 2716/4885
US-20130123280-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 RAB9A 1841/4885NPC1 2104/4885L3MBTL1 2456/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 RAB9A 1816/4885NPC1 6/4885L3MBTL1 2965/4885
US-20030134853-A1 Compounds useful for treating hepatitis C virus OAT, HAVCR2, GOT1 RAB9A 3330/4885NPC1 50/4885L3MBTL1 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.